REFERENCES
1. Arshad, T.; Golabi, P.; Paik, J.; Mishra, A.; Younossi, Z. M. Prevalence of nonalcoholic fatty liver disease in the female population. Hepatol. Commun. 2019, 3, 74-83.
2. Younossi, Z.; Anstee, Q. M.; Marietti, M.; et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 11-20.
3. Powell, E. E.; Wong, V. W.; Rinella, M. Non-alcoholic fatty liver disease. Lancet 2021, 397, 2212-24.
4. Musso, G.; Saba, F.; Cassader, M.; Gambino, R. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): recent advances. Prog. Lipid. Res. 2023, 91, 101238.
5. Walker, R. W.; Belbin, G. M.; Sorokin, E. P.; et al. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank. J. Hepatol. 2020, 72, 1070-81.
6. Hassani Zadeh, S.; Mansoori, A.; Hosseinzadeh, M. Relationship between dietary patterns and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2021, 36, 1470-8.
7. Dolce, A.; Della, Torre. S. Sex, nutrition, and NAFLD: relevance of environmental pollution. Nutrients 2023, 15, 2335.
8. Midya, V.; Colicino, E.; Conti, D. V.; et al. Association of prenatal exposure to endocrine-disrupting chemicals with liver injury in children. JAMA. Netw. Open. 2022, 5, e2220176.
9. Sha, B.; Schymanski, E. L.; Ruttkies, C.; Cousins, I. T.; Wang, Z. Exploring open cheminformatics approaches for categorizing per- and polyfluoroalkyl substances (PFASs). Environ. Sci. Process. Impacts. 2019, 21, 1835-51.
10. Langberg, H. A.; Breedveld, G. D.; Kallenborn, R.; et al. Human exposure to per- and polyfluoroalkyl substances (PFAS) via the consumption of fish leads to exceedance of safety thresholds. Environ. Int. 2024, 190, 108844.
11. He, Y.; Lv, D.; Li, C.; Liu, X.; Liu, W.; Han, W. Human exposure to F-53B in China and the evaluation of its potential toxicity: an overview. Environ. Int. 2022, 161, 107108.
12. Wu, B.; Pan, Y.; Li, Z.; et al. Serum per- and polyfluoroalkyl substances and abnormal lipid metabolism: a nationally representative cross-sectional study. Environ. Int. 2023, 172, 107779.
13. Mamsen, L. S.; Björvang, R. D.; Mucs, D.; et al. Concentrations of perfluoroalkyl substances (PFASs) in human embryonic and fetal organs from first, second, and third trimester pregnancies. Environ. Int. 2019, 124, 482-92.
14. Evich, M. G.; Davis, M. J. B.; McCord, J. P.; et al. Per- and polyfluoroalkyl substances in the environment. Science 2022, 375, eabg9065.
15. Domingo, J. L. A review of the occurrence and distribution of per- and polyfluoroalkyl substances (PFAS) in human organs and fetal tissues. Environ. Res. 2025, 272, 121181.
16. Wahlang, B.; Jin, J.; Beier, J. I.; et al. Mechanisms of environmental contributions to fatty liver disease. Curr. Environ. Health. Rep. 2019, 6, 80-94.
17. Foulds, C. E.; Treviño, L. S.; York, B.; Walker, C. L. Endocrine-disrupting chemicals and fatty liver disease. Nat. Rev. Endocrinol. 2017, 13, 445-57.
18. Das, K. P.; Wood, C. R.; Lin, M. T.; et al. Perfluoroalkyl acids-induced liver steatosis: effects on genes controlling lipid homeostasis. Toxicology 2017, 378, 37-52.
19. Borghese, M. M.; Liang, C. L.; Owen, J.; Fisher, M. Individual and mixture associations of perfluoroalkyl substances on liver function biomarkers in the Canadian Health Measures Survey. Environ. Health. 2022, 21, 85.
20. Mora, A. M.; Fleisch, A. F.; Rifas-Shiman, S. L.; et al. Early life exposure to per- and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environ. Int. 2018, 111, 1-13.
21. Stratakis, N.; V, Conti. D.; Jin, R.; et al. Prenatal exposure to perfluoroalkyl substances associated with increased susceptibility to liver injury in children. Hepatology 2020, 72, 1758-70.
22. Wu, Z.; Ouyang, T.; Liu, H.; Cao, L.; Chen, W. Perfluoroalkyl substance (PFAS) exposure and risk of nonalcoholic fatty liver disease in the elderly: results from NHANES 2003-2014. Environ. Sci. Pollut. Res. Int. 2023, 30, 64342-51.
23. Jin, R.; McConnell, R.; Catherine, C.; et al. Perfluoroalkyl substances and severity of nonalcoholic fatty liver in Children: an untargeted metabolomics approach. Environ. Int. 2020, 134, 105220.
24. Cao, Z.; Lin, S.; Zhao, F.; et al. Cohort profile: China National Human Biomonitoring (CNHBM) - a nationally representative, prospective cohort in Chinese population. Environ. Int. 2021, 146, 106252.
25. Wu, Y.; Cheng, Z.; Zhang, W.; et al. Association between per- and poly-fluoroalkyl substances and nonalcoholic fatty liver disease: a nested case-control study in Northwest China. Environ. Pollut. 2024, 350, 123937.
26. Fan, J. G.; Xu, X. Y.; Yang, R. X.; et al.; Chinese Society of Hepatology, Chinese Medical Association. Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (Version 2024). J. Clin. Transl. Hepatol. 2024, 12, 955-74.
27. Qu, Y.; Lv, Y.; Ji, S.; et al. Effect of exposures to mixtures of lead and various metals on hypertension, pre-hypertension, and blood pressure: a cross-sectional study from the China National Human Biomonitoring. Environ. Pollut. 2022, 299, 118864.
28. Wang, J.; Pan, Y.; Wei, X.; Dai, J. Temporal trends in prenatal exposure (1998-2018) to emerging and legacy per- and polyfluoroalkyl substances (PFASs) in cord plasma from the Beijing Cord Blood Bank, China. Environ. Sci. Technol. 2020, 54, 12850-9.
29. Lin, Q.; Wang, J.; Li, J. J.; et al. [Determination of 17 perfluorinated/polyfluoroalkyl compounds in serum by high-throughput solid-phase extraction-ultra-high performance liquid chromatography-tandem mass spectrometry]. Se. Pu. 2025, 43, 252-60.
30. Nomura, T.; Ono, M.; Kobayashi, K.; et al. Validation of fatty liver index as a predictor of hepatic steatosis in Asian populations: impact of alcohol consumption and sex. Hepatol. Res. 2023, 53, 968-77.
31. Li, B.; Liu, Y.; Ma, X.; Guo, X. The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and hepatic steatosis and liver fibrosis among US adults based on NHANES. Sci. Rep. 2025, 15, 6527.
32. de Silva, M. H. A. D.; Hewawasam, R. P.; Kulatunge, C. R.; Chamika, R. M. A. The accuracy of fatty liver index for the screening of overweight and obese children for non-alcoholic fatty liver disease in resource limited settings. BMC. Pediatr. 2022, 22, 511.
33. Feeney, T.; Hartwig, F. P.; Davies, N. M. How to use directed acyclic graphs: guide for clinical researchers. BMJ 2025, 388, e078226.
34. Chen, Y.; Cheng, Q.; Yang, C.; et al. From association to mechanism: prenatal PFAS co-exposures induces fetal neural tube defects via autophagy-mediated ferroptosis. J. Hazard. Mater. 2026, 502, 140979.
35. Qiao, W.; Li, J.; Luo, L.; et al. Triglycerides mediate the relationships of per- and poly-fluoroalkyl substance (PFAS) exposure with nonalcoholic fatty liver disease (NAFLD) risk in US participants. Ecotoxicol. Environ. Saf. 2025, 289, 117436.
36. David, N.; Antignac, J. P.; Roux, M.; et al. Associations between perfluoroalkyl substances and the severity of non-alcoholic fatty liver disease. Environ. Int. 2023, 180, 108235.
37. Xue, R.; Nie, X.; Ballah, J.; et al. Systemic chronic inflammation mediates the effect of per- and polyfluoroalkyl substances exposure on the risk of nonalcoholic fatty liver disease: a cross-sectional study among Chinese government employees. Environ. Epidemiol. 2025, 9, e411.
38. Zhang, X.; Zhao, L.; Ducatman, A.; et al. Association of per- and polyfluoroalkyl substance exposure with fatty liver disease risk in US adults. JHEP. Rep. 2023, 5, 100694.
39. Momo, H. D.; Alvarez, C. S.; Purdue, M. P.; Graubard, B. I.; McGlynn, K. A. Associations of per- and polyfluoroalkyl substances and nonalcoholic fatty liver disease in the United States adult population, 2003-2018. Environ. Epidemiol. 2024, 8, e284.
40. Wu, M.; Zhu, Z.; Wan, R.; Xu, J. Exposure to per- and polyfluoroalkyl substance and metabolic syndrome: a nationally representative cross-sectional study from NHANES, 2003-2018. Environ. Pollut. 2024, 346, 123615.
41. Hwang, S. H.; Choi, Y. H.; Huh, D. A.; et al. Per- and polyfluoroalkyl substances exposures are associated with non-alcoholic fatty liver disease, particularly fibrosis. Environ. Pollut. 2025, 372, 126085.
42. E, L.; Zhang, S.; Jiang, X. Association between perfluoroalkyl substances exposure and the prevalence of nonalcoholic fatty liver disease in the different sexes: a study from the National Health and Nutrition Examination Survey 2005-2018. Environ. Sci. Pollut. Res. Int. 2023, 30, 44292-303.
43. Morán-Costoya, A.; Proenza, A. M.; Gianotti, M.; Lladó, I.; Valle, A. Sex differences in nonalcoholic fatty liver disease: estrogen influence on the liver-adipose tissue crosstalk. Antioxid. Redox. Signal. 2021, 35, 753-74.
44. Chen, H.; Liu, Y.; Liu, D.; et al. Sex- and age-specific associations between abdominal fat and non-alcoholic fatty liver disease: a prospective cohort study. J. Mol. Cell. Biol. 2024, 15, mjad069.
45. Spooner, M. H.; Jump, D. B. Nonalcoholic fatty liver disease and omega-3 fatty acids: mechanisms and clinical use. Annu. Rev. Nutr. 2023, 43, 199-223.
46. Tan, L. J.; Shin, S. Effects of oily fish and its fatty acid intake on non-alcoholic fatty liver disease development among South Korean adults. Front. Nutr. 2022, 9, 876909.
47. Scorletti, E.; Byrne, C. D. Omega-3 fatty acids and non-alcoholic fatty liver disease: evidence of efficacy and mechanism of action. Mol. Aspects. Med. 2018, 64, 135-46.
48. Tatoli, R.; Caterina, B.; Donghia, R.; Pesole, P. L.; Fontana, L.; Giannelli, G. Dietary omega-3 fatty acids from fish and risk of metabolic dysfunction-associated steatotic liver disease in a Mediterranean population: findings from the NUTRIHEP cohort. Nutrients 2025, 17, 3372.
49. Recaredo, G.; Marin-Alejandre, B. A.; Cantero, I.; et al. Association between different animal protein sources and liver status in obese subjects with non-alcoholic fatty liver disease: fatty liver in obesity (FLiO) study. Nutrients 2019, 11, 2359.
50. He, X.; Wu, R.; Jiang, W.; Tian, Y.; Zhang, J.; Huang, Y.; Shanghai Birth Cohort. Prenatal exposure to per- and polyfluoroalkyl substances and childhood executive function and behavioral difficulties at age 7: evidence from the Shanghai birth cohort study. Environ. Int. 2025, 202, 109687.
51. Yun, J.; Min, Y. S. Association between perfluoroalkyl substance (PFAS) exposure and nonalcoholic fatty liver disease in Korean adults: results from the KoNEHS 2018-2020: a cross-sectional study. Am. J. Ind. Med. 2025, 68, 588-97.
52. Du, X.; Li, D. L.; Xu, X.; et al. Effects of mixed exposure to PFAS on adolescent non-alcoholic fatty liver disease: Integrating evidence from human cohorts, toxicogenomics, and animal models to uncover mechanisms and potential target sites. J. Hazard. Mater. 2025, 485, 136854.
53. Cheng, W.; Li, M.; Zhang, L.; et al. Close association of PFASs exposure with hepatic fibrosis than steatosis: evidences from NHANES 2017-2018. Ann. Med. 2023, 55, 2216943.
54. Li, X.; Wang, Z.; Klaunig, J. E. The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice. Toxicology 2019, 416, 1-14.
56. Pan, Z.; Miao, W.; Wang, C.; Tu, W.; Jin, C.; Jin, Y. 6:2 Cl-PFESA has the potential to cause liver damage and induce lipid metabolism disorders in female mice through the action of PPAR-γ. Environ. Pollut. 2021, 287, 117329.
57. Huang, J.; Liu, Y.; Wang, Q.; et al. Concentration-dependent toxicokinetics of novel PFOS alternatives and their chronic combined toxicity in adult zebrafish. Sci. Total. Environ. 2022, 839, 156388.
58. Qi, Q.; Niture, S.; Gadi, S.; et al. Per- and polyfluoroalkyl substances activate UPR pathway, induce steatosis and fibrosis in liver cells. Environ. Toxicol. 2023, 38, 225-42.
59. Weng, Z.; Xu, C.; Zhang, X.; et al. Autophagy mediates perfluorooctanoic acid-induced lipid metabolism disorder and NLRP3 inflammasome activation in hepatocytes. Environ. Pollut. 2020, 267, 115655.
60. Sen, P.; Qadri, S.; Luukkonen, P. K.; et al. Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease. J. Hepatol. 2022, 76, 283-93.
